“Major depressive disorder” is another name for clinical ... It can take time to find a treatment plan that works, but many people find that their symptoms respond well to a combination ...

For the twenty-one million American adults experiencing major depressive disorder (MDD) annually, this FDA-cleared treatment ...

Researchers have identified structural gray matter differences in the brains of women with a history of peripartum depression and those without within a group of major depressive disorder patients.

A University of Queensland-led team analyzed data for 204 countries and territories, to assess global access to adequate ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

Relmada Therapeutics' depression treatment is "unlikely" to meet the main goal of a late-stage trial, it said on Wednesday, citing an independent data monitoring committee's analysis. The treatment, ...

Relmada Therapeutics lost more than two-thirds of its market value early Wednesday after the biotechnology company said a treatment for major depressive disorder would likely fail to meet its primary ...

Relmada is now scrapping Reliance II, plus another phase 3 trial called Relight, which was assessing REL-1017 as an add-on ...

Relmada Therapeutics said an interim analysis of a study assessing a treatment for major depressive disorder is futile and unlikely to meet the primary efficacy endpoint with statistical significance.

Psilocybin-assisted therapy, which involves using the active ingredient from "magic mushrooms," could benefit roughly 5 ...

its Phase 3 pivotal program evaluating the efficacy and safety of CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”). The program name, PARADIGM, represents the Company's ...